AbstractCrowdfunding is an evolving popular Internet-based process used to raise funding that has been employed by a few start-ups in the biotechnology industry. To solicit crowdfunding, companies profile their case on a specialized web platform (generally called a â€œcrowdfunding portalâ€) to site members (i.e., the â€œcrowdâ€) who choose which projects they would like to fund, in exchange for financial and nonfinancial inducements. We examine the evolving commercial and regulatory crowdfunding landscape and also identifies case studies of biotechnology industry use. We have found that a variety of crowdfunding mechanisms have been used and this alternative financing strategy may represent a viable option for biotechnology start-ups during early stage research or early stage clinical trials. A successful crowdfunding campaign may pave the way for the enterpriseâ€™s future capital formation phases by attracting angel investors or venture capital because it shows that the business or project is viable. Crowdfunding, like all other forms of capital formation, requires careful planning and execution before, during, and after a campaign. Strategies that appropriately tap into this innovative and disruptive use of technology and social networks may prove to be a unique capital formation niche for biotechnology start-ups; one that has yet to be fully leveraged.
Deloitte Technology (April 25, 2014). Deloitte Insights. More Than Just Crowdfunding: Two Years After the JOBS Act. Available online from: http://deloitte.wsj.com/cfo/2014/04/25/more-than-just-crowdfunding-two-years-after-the-jobs-act/ accessed 20 June 2015.
Investopedia. Dictionary. Crowdfunding. Available online from: http://www.investopedia.com/terms/c/crowdfunding.asp accessed 20 June 2015.
Jumpstart Our Business Startups Act. Pub. L. 112-108,secs 301to 305 126 Stat. 306. 2012. Available online from: http://www.gpo.gov/fdsys/pkg/PLAW-112publ106/pdf/PLAW-112publ106.pdf, accessed 20 June 2015.
U.S. Securities and Exchange Commission (Oct. 23, 2013). Crowdfunding (Proposed Rules). Available online from: www.sec.gov/rules/proposed/2013/33-9470.pdf, pp. 18, 36, 38, 41, 123, 128, 329, 330â€“332, accessed 20 June 2015.
U.S. Securities and Exchange Commission. Division of Trading and Markets (May 7, 2012). Jumpstart Our Business Startups Act. Frequently Asked Questions About Crowdfunding Intermediaries. Available online from: https://www.sec.gov/divisions/marketreg/tmjobsact-crowdfundingintermediariesfaq.htm accessed 20 June 2015.
Debaise, C. (18 April 2010). Whatâ€™s an Angel Investor? The Wall Street Journal. Available online from: http://www.wsj.com/articles/SB10001424052702303491304575188420191459904, accessed 20 June 2015.
Angel Capital Association. FAQs About Angel Investors. Available online from: http://www.angelcapitalassociation.org/faqs/, accessed 20 June 2015.
Angel Capital Association. FAQs on Angel Investing. Available online from: http://www.angelcapitalassociation.org/faqs/#When_should_I_approach_an_angel_group_, accessed 20 June 2015.
Bradford, C.S. (9 Mar. 2012) Crowdfunding and the Federal Securities Laws. Columbia Business Law Review. 2012(1).
Kirby, E., and Worner, S. (Feb. 2014) Crowd-funding: An Infant Industry Growing Fast. International Organization of Securities Commissions. Report number: SWP3. Available from: https://www.iosco.org/research/?subSection=staff_working_papers, accessed 20 June 2015.
Charity Navigator. (FYE Jun. 2013) Cancer Research Institute â€“ Current Rating. Available online from: http://www.charitynavigator.org/index.cfm?bay=search.summary&orgid=3417#.VY-hPflVikp, accessed 20 June 2015.
Charity Navigator. (FYE Jun. 2014) Pediatric Cancer Foundation â€“ Current Rating. Available online from: http://www.charitynavigator.org/index.cfm?bay=search.summary&orgid=11248#.VY-e9vlVikp accessed 20 June 2015].
Hoekstra, A., and Estep, P. (2013) Crowdcuring the Blues: People, Technology and Research Against Depression. Available online from: https://experiment.com/projects/crowdcuring-the-blues-ending-depression-for-good, accessed 20 June 2015.
Wagner, J., Ryazanov, S., Leonov, A., et al. (2013) Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinsonâ€™s disease. Acta Neuropathologica 125(6): 795â€“813, doi: 10.1007/s00401-013-1114-9.
Vallabh, S., and Minikel, E. (2013) Can anle138b delay the onset of genetic prion disease? Available online from: https://experiment.com/projects/can-anle138b-delay-the-onset-of-genetic-prion-disease, accessed 20 June 2015.
Iorns, E. (2013) Can we prevent the transmission of BRCA mutations? Available online from: https://experiment.com/projects/can-we-prevent-the-transmission-of-brca-mutations, accessed 20 June 2015.
Howe, J. (2008) Crowdsourcing: Why the Power of the Crowd Is Driving the Future of Business. New York: Crown Business Publishing.
Hendrickson, M. 8 Apr 2008) Lending Club Puts Hold on Lending Activity While It Sorts Out Some Legal Issues. Available online from: http://techcrunch.com/2008/04/08/lending-club-puts-moratorium-on-lending-activity/, accessed 20 June 2015.
Chapman and Cutler LLP. (2015) The Regulation of Marketplace Lending â€“ A Summary of the Principal Issues. (2015 Update). Available online from: http://www.aba.com/Tools/Offers/Documents/Chapman.pdf, accessed 4 June 2015.
U.S. Government Publishing Office. Electronic Code of Federal Regulations (Part 230). Available online from: http://www.ecfr.gov/cgi-bin/text-idx?SID=465dc4251925603a672a767b7916fc49&node=sg17.3.230_1498.sg11&rgn=div7, accessed 28 June 2015.
Investor.gov U.S. Securities and Exchange Commission. (23 Sep 2013) Investor Bulletin: Accredited Investors. Available online from: http://www.investor.gov/news-alerts/investor-bulletins/investor-bulletin-accredited-investors, accessed 28 June 2015.
Indiegogo. (2015) About Us. Available online from: https://www.indiegogo.com/about/our-story, accessed 26 May 2015.
Exogen Biotechnology. (2014) How damaged is your DNA? Available online from: https://www.indiegogo.com/projects/exogen-bio-how-damaged-is-your-dna#/story, accessed 26 May 2015.
SyndicateRoom. (Apr 2014) Success Stories: Apta Biosciences. Available online from: https://www.syndicateroom.com/about-us/success-stories/apta-biosciences.aspx, accessed 26 June 2015.
LinkedIn. Apta Biosciences Ltd. [Online] Available from: https://www.linkedin.com/company/3241697?trk=tyah&trkInfo=clickedVertical%3Acompany%2Cidx%3A1-1-1%2CtarId%3A1433497927487%2Ctas%3AApta%20Bio accessed 26 June 2015].
SyndicateRoom. SyndicateRoom â€“ A new way of investing. Available online from: https://www.syndicateroom.com/faqs.aspx, accessed 26 June 2015.
Apta Biosciences. (2014) Introducing Seligos from Apta. Available online from: http://www.aptabiosciences.com/, accessed 26 June 2015.
ImPatient. Support the new non-profit changing the way charitable money funds medical research. Available online from: http://www.beimpatient.org/, accessed 20 May 2015.
Pena, S. (21 Nov 2013) Crowdfunding platform ImPatient wins Lehigh Valley Startup Weekend. Available online from: http://www.keystoneedge.com/features/lehighvalleystartupweekend1121.aspx accessed 20 May 2015.
Baum, S. (21 Apr 2014) Here are five different approaches to crowdfunding for biotechnology. MedCity News. Available online from: http://medcitynews.com/2014/04/here-are-five-different-approaches-to-crowdfunding-for-biotechnology/, accessed 26 May 2015.
Financial Conduct Authority. (2 Feb 2015) A review of the regulatory regime for crowdfunding and the promotion of non-readily realisable securities by other media. Available online from: http://www.fca.org.uk/your-fca/documents/crowdfunding-review, accessed 26 June 2015.
Briggman, S. Top 11 Debt Crowdfunding Sites. Blog entry, n.d . Available online from: http://www.crowdcrux.com/debt-crowdfunding-sites/, accessed 26 June 2015.
Clark, P. (17 July 2014) Funding Circle Raises $65 Million for Peer-to-Peer Small Business Loans. Bloomberg Business News. http://www.bloomberg.com/bw/articles/2014-07-17/will-funding-circles-65-million-help-it-compete-with-banks, accessed 27 May 2015.
Unless specified by prior arrangement, the author agrees to the following terms and assurances:
- For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
- I/we further give to the following assurances
- I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
- I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
- To the best of my/our knowledge, all the facts in the contribution are true and accurate;
- The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
- Nothing in the contribution is obscene or libellous;
- Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
- I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).